PRGN-3006

PRGN-3006 is a multigenic, autologous chimeric antigen receptor T cell (CAR-T) therapy developed by Precigen for the treatment of hematologic malignancies. It is engineered using a non-viral system to express a CAR targeting CD33, membrane-bound interleukin-15 (mbIL15) to enhance in vivo expansion and persistence of the CAR-T cells, and an inducible kill switch for improved safety. The therapy is designed to selectively target and eliminate CD33-positive tumor cells while allowing for controlled depletion of the CAR-T cells if needed. Its primary indications are relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS). PRGN-3006 has received orphan drug designation and fast track status from the FDA for AML[1][5][7][8].

Brand names

UltraCAR-T

Other names

autologous anti-CD33 CAR-mbIL15-safety switch T cellsPRGN-3006 UltraCAR-TPRGN3006 UltraCAR-TPRGN 3006 UltraCAR-TUltraCAR-T